Skip to content
Home / Companies / QURE QUR
uniQure N.V. (QURE) XNAS PHARMACEUTICAL PREPARATIONS Net insider selling (90d)
Latest QURE Insider Trades
About uniQure N.V. (QURE) uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Headquarters AMSTERDAM
Employees 221
Listed 2014
Exchange XNAS https://www.uniqure.com SEC filings for QURE on EDGAR
90-Day SEC Filing Activity Form 4 transaction type Transactions Shares Total value Open-market sale 36 388,229 $16.82M Grant or award 14 150,710 Option exercise 28 369,200
QURE Insider Transactions (Form 4) 101 41 Form 4 filings on record, the earliest from Dec 10, 2024, newest first. Filing history page 1 of 2.
Date Insider Transaction Security Shares Price Value Jul 2, 2026 MK Matthew C. Kapusta - Officer Option exercise Ordinary Shares 21,082
Recent QURE Form 8-K Filings 5
Recent QURE Form 144 Notices of Proposed Sale 3 A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
Filed Filer Relationship Shares Market value Notice Jul 2, 2026 - - - - View on EDGAR Jun 30, 2026 - - -
QURE Insider Trading - FAQ
What is the latest insider trade for QURE? uniQure N.V. (QURE) had 19 insider filings in the last 90 days, with the most recent on 2026-07-07. The full record for QURE runs to 41 Form 4 filings, the earliest from 2024-12-10. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying QURE stock? No insider purchases of QURE were filed in the last 90 days.
How many insiders are selling QURE stock? 36 insider sales of QURE were filed in the last 90 days, totaling $16.82M.
Where can I see QURE SEC filings (Form 4, 10-K, 10-Q, 8-K)? This page tracks QURE Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow QURE insider buys? Create a free InsiderAlpha account and press Watch on this page to add QURE to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Health Care Companies with Insider Activity Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Related Companies - Recent Insider Activity What is SEC Form 4? The filing insiders must submit within two business days of a trade, and how to read its transaction codes. Track QURE insider activity as it files Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
Sign up free JK Jack Kaye - Director Open-market sale $191K
Jun 30, 2026
JK Jack Kaye - Director Open-market sale $792K
Jun 30, 2026
Market cap $3.38B
P/E ratio -
Dividend yield -
Average volume 1.88M
52 week high $71.50
52 week low $8.73
Today's high $49.51
Today's low $48.29
Open $49.51
Volume 843.7K
Previous close $49.56
Shares outstanding 69.37M Market cap
$3.38B
221 employees
QURE Insider Sentiment - Last 90 Days Share of open-market insider dollar volume that was buying versus selling, from SEC Form 4 filings.
0% Buying 100% Selling
0 insider purchases totaling $0 against 36 sales totaling $16.82M.
Most-Active QURE Insiders - Last 90 Days 10 Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
Jul 2, 2026 MK Matthew C. Kapusta - Officer Option exercise Stock Option (Right to Buy) 21,082 $0.00 -
Jun 30, 2026 WA Walid Abi-Saab - Officer Open-market sale Ordinary Shares 10,000 $46.46 $465K
Jun 30, 2026 WA Walid Abi-Saab - Officer Open-market sale Ordinary Shares 20,000 $46.40 $928K
Jun 30, 2026 WA Walid Abi-Saab - Officer Option exercise Stock Option (Right to Buy) 10,000 $0.00 -
Jun 30, 2026 WA Walid Abi-Saab - Officer Option exercise Ordinary Shares 10,000 $5.59 $56K
Jun 30, 2026 JK Jack Kaye - Director Option exercise Ordinary Shares 4,107 $37.00 $152K
Jun 30, 2026 JK Jack Kaye - Director Open-market sale Ordinary Shares 4,107 $46.49 $191K
Jun 30, 2026 JK Jack Kaye - Director Option exercise Ordinary Shares 17,060 $20.18 $344K
Jun 30, 2026 JK Jack Kaye - Director Open-market sale Ordinary Shares 17,060 $46.43 $792K
Jun 30, 2026 JK Jack Kaye - Director Option exercise Stock Option (Right to Buy) 4,107 $0.00 -
Jun 30, 2026 JK Jack Kaye - Director Option exercise Stock Option (Right to Buy) 17,060 $0.00 -
Jun 26, 2026 WA Walid Abi-Saab - Officer Open-market sale Ordinary Shares 1,434 $46.86 $67K
Jun 25, 2026 MK Matthew C. Kapusta - Officer Open-market sale Ordinary Shares 28,716 $50.02 $1.44M
Jun 24, 2026 MK Matthew C. Kapusta - Officer Option exercise Stock Option (Right to Buy) 4,128 $0.00 -
Jun 25, 2026 MK Matthew C. Kapusta - Officer Option exercise Stock Option (Right to Buy) 28,716 $0.00 -
Jun 18, 2026 MK Matthew C. Kapusta - Officer Open-market sale Ordinary Shares 37,015 $50.00 $1.85M
Jun 17, 2026 MK Matthew C. Kapusta - Officer Option exercise Stock Option (Right to Buy) 62,581 $0.00 -
Jun 18, 2026 MK Matthew C. Kapusta - Officer Option exercise Stock Option (Right to Buy) 4,656 $0.00 -
Jun 17, 2026 MK Matthew C. Kapusta - Officer Option exercise Ordinary Shares 62,581 $19.39 $1.21M
Jun 17, 2026 MK Matthew C. Kapusta - Officer Open-market sale Ordinary Shares 23,977 $42.61 $1.02M
Jun 17, 2026 MK Matthew C. Kapusta - Officer Open-market sale Ordinary Shares 32,581 $45.02 $1.47M
Jun 17, 2026 MK Matthew C. Kapusta - Officer Open-market sale Ordinary Shares 56,929 $43.43 $2.47M
Jun 17, 2026 MK Matthew C. Kapusta - Officer Open-market sale Ordinary Shares 33,334 $45.01 $1.50M
Jun 17, 2026 MK Matthew C. Kapusta - Officer Open-market sale Ordinary Shares 11,585 $48.65 $564K
Jun 17, 2026 JK Jack Kaye - Director Option exercise Ordinary Shares 5,295 $31.71 $168K
Jun 17, 2026 JK Jack Kaye - Director Open-market sale Ordinary Shares 5,295 $42.57 $225K
Jun 17, 2026 JK Jack Kaye - Director Option exercise Stock Option (Right to Buy) 5,295 $0.00 -
Jun 15, 2026 JP Jeannette Potts - Officer Open-market sale Ordinary Shares 5,237 $27.67 $145K
Jun 11, 2026 DM David D. Meek - Director Open-market sale Ordinary Shares 1,993 $27.06 $54K
Jun 10, 2026 DM David D. Meek - Director Grant or award Stock Option (Right to Buy) 13,980 $0.00 -
Jun 10, 2026 DM David D. Meek - Director Grant or award Ordinary Shares 7,550 $0.00 -
Jun 10, 2026 RG Robert Gut - Director Open-market sale Ordinary Shares 3,127 $26.03 $81K
Jun 10, 2026 RG Robert Gut - Director Open-market sale Ordinary Shares 1,780 $26.05 $46K
Jun 10, 2026 RG Robert Gut - Director Grant or award Ordinary Shares 7,550 $0.00 -
Jun 11, 2026 RG Robert Gut - Director Open-market sale Ordinary Shares 2,726 $27.06 $74K
Jun 10, 2026 RG Robert Gut - Director Option exercise Stock Option (Right to Buy) 2,645 $0.00 -
Jun 10, 2026 RG Robert Gut - Director Grant or award Stock Option (Right to Buy) 13,980 $0.00 -
Jun 10, 2026 RG Robert Gut - Director Option exercise Ordinary Shares 2,645 $16.04 $42K
Jun 10, 2026 RG Robert Gut - Director Open-market sale Ordinary Shares 2,645 $26.07 $69K
Jun 11, 2026 KO Kylie O'Keefe - Officer Open-market sale Ordinary Shares 15,936 $27.06 $431K
Jun 10, 2026 LP Leonard E. Post - Director Grant or award Stock Option (Right to Buy) 13,980 $0.00 -
Jun 10, 2026 LP Leonard E. Post - Director Grant or award Ordinary Shares 7,550 $0.00 -
Jun 11, 2026 LP Leonard E. Post - Director Open-market sale Ordinary Shares 1,993 $27.06 $54K
Jun 11, 2026 JK Jack Kaye - Director Open-market sale Ordinary Shares 1,993 $27.06 $54K
Jun 10, 2026 JK Jack Kaye - Director Grant or award Stock Option (Right to Buy) 13,980 $0.00 -
Jun 10, 2026 JK Jack Kaye - Director Grant or award Ordinary Shares 7,550 $0.00 -
Jun 3, 2026 JK Jack Kaye - Director Option exercise Ordinary Shares 2,645 $16.04 $42K
Jun 3, 2026 JK Jack Kaye - Director Open-market sale Ordinary Shares 2,645 $30.01 $79K
Jun 3, 2026 JK Jack Kaye - Director Option exercise Stock Option (Right to Buy) 2,645 $0.00 -
May 8, 2026 WA Walid Abi-Saab - Officer Option exercise Ordinary Shares 25,000 $5.59 $140K
May 8, 2026 WA Walid Abi-Saab - Officer Open-market sale Ordinary Shares 25,000 $25.10 $628K
May 8, 2026 WA Walid Abi-Saab - Officer Open-market sale Ordinary Shares 20,000 $25.00 $500K
May 8, 2026 WA Walid Abi-Saab - Officer Option exercise Stock Option (Right to Buy) 25,000 $0.00 -
Mar 4, 2026 KO Kylie O'Keefe - Officer Grant or award Ordinary Shares 19,800 $0.00 -
Mar 4, 2026 KO Kylie O'Keefe - Officer Grant or award Stock Option (Right to Buy) 31,900 $0.00 -
Mar 4, 2026 MK Matthew C. Kapusta - Officer Grant or award Stock Option (Right to Buy) 113,800 $0.00 -
Mar 4, 2026 WA Walid Abi-Saab - Officer Grant or award Stock Option (Right to Buy) 67,200 $0.00 -
Mar 4, 2026 WA Walid Abi-Saab - Officer Grant or award Ordinary Shares 41,700 $0.00 -
Mar 4, 2026 WA Walid Abi-Saab - Officer Open-market sale Ordinary Shares 808 $9.06 $7K
Mar 4, 2026 JP Jeannette Potts - Officer Grant or award Stock Option (Right to Buy) 57,200 $0.00 -
Mar 4, 2026 JP Jeannette Potts - Officer Grant or award Ordinary Shares 35,400 $0.00 -
Mar 4, 2026 JP Jeannette Potts - Officer Open-market sale Ordinary Shares 3,412 $9.06 $31K
Mar 4, 2026 CK Christian Klemt - Officer Grant or award Ordinary Shares 39,600 $0.00 -
Mar 4, 2026 CK Christian Klemt - Officer Open-market sale Ordinary Shares 12,000 $9.06 $109K
Mar 4, 2026 CK Christian Klemt - Officer Grant or award Stock Option (Right to Buy) 63,900 $0.00 -
Mar 2, 2026 CK Christian Klemt - Officer Open-market sale Ordinary Shares 12,532 $9.95 $125K
Mar 2, 2026 JP Jeannette Potts - Officer Open-market sale Ordinary Shares 8,578 $9.95 $85K
Mar 2, 2026 WA Walid Abi-Saab - Officer Open-market sale Ordinary Shares 1,660 $9.95 $17K
Feb 25, 2026 MK Matthew C. Kapusta - Officer Open-market sale Ordinary Shares 12,378 $23.86 $295K
RCU $IONS
IONIS PHARMACEUTICALS INC
